08.01.2014 Views

Management of pregnancy - VA/DoD Clinical Practice Guidelines ...

Management of pregnancy - VA/DoD Clinical Practice Guidelines ...

Management of pregnancy - VA/DoD Clinical Practice Guidelines ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>VA</strong>/<strong>DoD</strong> <strong>Clinical</strong> <strong>Practice</strong> Guideline<br />

For Pregnancy <strong>Management</strong><br />

• Late entry counseling. This counseling should be provided to women presenting for prenatal care when the<br />

gestational age <strong>of</strong> her <strong>pregnancy</strong> limits options for screening strategies or diagnostic testing. The<br />

counseling should be based on the individual circumstances including the gestational age and patient<br />

desires.<br />

EVIDENCE TABLE<br />

Recommendations Sources <strong>of</strong> Evidence LE QE SR<br />

1 All women, regardless <strong>of</strong> age, should<br />

be <strong>of</strong>fered aneuploidy screening<br />

2 When discussing options with patients,<br />

providers should furnish information<br />

on detection and false positive rates,<br />

advantages and disadvantages <strong>of</strong> each<br />

testing method<br />

ACOG, 2007 III Fair B<br />

ACOG, 2007 III Fair B<br />

3 Unique benefits with each type <strong>of</strong><br />

intervention: individual counseling,<br />

group counseling sessions, and use <strong>of</strong><br />

decision aids and audiovisual<br />

presentation<br />

5 First-trimester screening can lead to a<br />

diagnosis <strong>of</strong> fetal aneuploidy much<br />

earlier<br />

6 Measurement <strong>of</strong> nuchal translucency<br />

alone is less effective for first-trimester<br />

screening than is the combined test<br />

(nuchal translucency measurement and<br />

biochemical markers)<br />

Hunter et al., 2005<br />

Fries et al., 2005<br />

ACOG, 2007<br />

Malone et al., 2003, 2005<br />

Wapner et al., 2003<br />

Wald et al., 2003<br />

Nicolaides et al., 2004<br />

Snijders et al., 2002<br />

I Fair B<br />

I Good A<br />

IIb Fair B<br />

7 Patients undergoing first-trimester<br />

screening for aneuploidy should be<br />

<strong>of</strong>fered maternal serum alpha<br />

fetoprotein (MSAFP) in the second<br />

trimester to screen for open neural tube<br />

defects<br />

Lennon et al., 1999<br />

Nicolaides et al., 1992<br />

II Fair B<br />

LE = Level <strong>of</strong> Evidence; QE = Quality <strong>of</strong> Evidence; SR = Strength <strong>of</strong> Recommendation (See Appendix A)<br />

Interventions Page - 75

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!